Patents
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
04/2010
04/22/2010US20100098628 Proteins
04/22/2010US20100098627 Proteins
04/22/2010US20100098626 Protein
04/22/2010US20100098625 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
04/22/2010US20100098624 Method for using cdo antagonists to modulate hedgehog signaling
04/21/2010EP2177232A2 Activation and production of radiolabeled particles
04/21/2010EP2176295A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use
04/21/2010EP2175888A2 Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
04/21/2010EP2175887A1 Compositions for delivery of therapeutics and other materials
04/21/2010CN101695574A Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
04/21/2010CN101007777B (s)-(-)-5-tributyltin-N-[(1-allyl-2-pyrrolidinyl)methyl]-2,3-dimethoxybenzamide preparation method
04/20/2010US7700621 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
04/20/2010US7700564 Analgesic effect by administering a drug delivery system of glutathione carrier covalently bonded to the exterior surface of an intercalation compound of polyethylene glycol and Vitamin E or a phosphholipid; crosses the blood-brain barrier; nervous system disorders; carrier-mediated transcytosis
04/20/2010US7700561 Abuse-resistant amphetamine prodrugs
04/20/2010US7700550 Telavancin or its hydrochloride salt for infection, including MRSA infections; reduced tissue accumulation and/or nephrotoxicity
04/20/2010US7700073 Use of NF-κB inhibition in combination therapy for cancer
04/20/2010CA2359573C Conjugates of colony stimulating factors for targeting and imaging infection and inflammation
04/20/2010CA2185349C Radiolabeled annexin-galactose conjugates
04/15/2010WO2010042244A1 Pet scanning determination of lymph nodes enriched in 1241 labeled antibodies for cancer
04/15/2010WO2010041742A1 Method for introducing dota
04/15/2010WO2010000714A3 Radioimmunoconjugate purification
04/15/2010WO2009152222A3 Fluid bed meal containing a marker and methods of making
04/15/2010US20100094016 Thiazoline acid derivatives
04/15/2010US20100093003 Methods to impair hematologic cancer progenitor cells and compounds related thereto
04/15/2010US20100092387 Novel Compound Having Affinity For Amyloid
04/15/2010US20100092386 System for delivering therapeutic agents into living cells and cells nuclei
04/15/2010US20100092385 Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives
04/14/2010EP2174958A1 Antibodies derived from anti ed-b l19 and targeting tumor vasculature
04/14/2010CN101693724A Technetium-99m labeled propyl zoledronic acid composition and preparation method thereof
04/14/2010CN101693024A Radionuclide-labelled biodegradable bioabsorbable biopolymer nano fibrous membrane, preparation process and application thereof
04/14/2010CN101091799B Medicine in use for treating gastric cancer, and preparation method
04/13/2010US7696331 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
04/13/2010US7696149 Peptides present in form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts and administration forms also contain one of above acids as free acids; for treating sex hormone-dependent diseases
04/13/2010CA2257357C Humanized antibodies with modified glycosylation
04/13/2010CA2200868C Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies
04/08/2010WO2010039609A2 A version of fdg detectable by single-photon emission computed tomography
04/08/2010WO2010037856A2 DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS
04/08/2010WO2009109327A3 Method and product for obtaining thin radioactive layers to be used in radiation dosimetry and in medicine
04/08/2010US20100086480 Low radiocarbon dietary supplements and methods of making same
04/08/2010CA2738786A1 A version of fdg detectable by single-photon emission computed tomography
04/07/2010EP2172208A1 Small peptides for the treatment of Alzheimer's disease and other Beta-Amyloid protein fibrillogenesis disorders
04/07/2010EP2170405A2 Imaging diagnostics by combining contrast agents
04/06/2010US7691985 treating a bone-associated cancer while reducing the incidence of sustained renal dysfunction; radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
04/06/2010US7691977 Anti-VEGF antibodies
04/06/2010US7691967 Smart pro-drugs of serine protease inhibitors
04/06/2010US7691964 Contact Inhibitory Factor (CIF) mediated inhibition of tumor metastasis and angiogenesis
04/06/2010US7691806 Mixture of protein polymer and active materials
04/06/2010US7691405 Biodrug delivery; SiRNA, cationic lipid CLinDMA, Cholesterol, and a polvethyleneglycol-diacylglycamide (PEG-DAG)
04/06/2010US7691380 Coagulating the vascular systems of cancer cells through site specific delivery of coagulant antibodies causing regression of the cells
04/06/2010US7691376 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes
04/06/2010US7691285 Magnetic nanoparticles having improved magnetic properties
04/06/2010CA2553235C Method and kit for the production of particles labelled with rhenium-188
04/01/2010WO2010036837A1 Coordination of a technetium imaging complex on a bioactive apoptosis targeting agent
04/01/2010WO2010036140A1 Metal complexes, a method for preparing same, radiopharmaceutical means based thereon
04/01/2010WO2010035915A1 Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
04/01/2010WO2010006616A3 Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi)
04/01/2010WO2009114549A3 99mtc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical
04/01/2010WO2009102384A3 Radiolabeled derivatives of potent chymase inhibitors
04/01/2010WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody
04/01/2010US20100081795 Rg1 antibodies and uses thereof
04/01/2010US20100081609 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
04/01/2010US20100080775 Recombinant adenoviruses encoding the specific iodine transporter (nis)
04/01/2010US20100080756 Methods for protecting and regenerating bone marrow using cxcr3 agonists and antagonists
03/2010
03/31/2010CN101688183A Cancerous disease modifying antibodies
03/31/2010CN101687931A an anti-cancer cytotoxic monoclonal antibody
03/31/2010CN101687930A Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
03/31/2010CN101687803A Metal chelates having a perfluorinated peg group, method for the production thereof, and use thereof
03/31/2010CN101687780A ligands for imaging cardiac innervation
03/30/2010US7687607 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)
03/30/2010US7687467 for treatment of attention deficit hyperactivity disorder, narcolepsy; bioavailability
03/30/2010US7687466 Abuse-resistant amphetamine prodrugs
03/30/2010US7687454 Effectors of innate immunity determination
03/30/2010US7687052 radiolabeling; neurodegenerative diseases
03/30/2010CA2372786C Formable integral source material for medical and industrial devices
03/30/2010CA2241604C Mesothelium antigen and methods and kits for targeting it
03/25/2010WO2010032509A1 Molecular probe precursor for imaging of pancreatic islet, and use thereof
03/25/2010WO2010005697A3 18f-labelled three-and four-carbon acids for pet imaging
03/25/2010WO2009141090A9 {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
03/25/2010WO2009133362A3 Agents for detecting and imaging cell death
03/25/2010WO2009106564A3 Imaging the central nervous system
03/25/2010US20100076174 ErbB Interface Peptidomimetics And Methods Of Use Thereof
03/25/2010US20100074844 Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins
03/25/2010US20100074843 Novel Substrate Based PET Imaging Agents
03/25/2010US20100074842 Technetium-99m (I) Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging
03/25/2010US20100074841 Compositions Against Cancer Antigen LIV-1 and Uses Thereof
03/25/2010US20100074840 Anthracycline-Antibody Conjugates for Cancer Therapy
03/24/2010EP2164874A1 Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity
03/24/2010EP2164525A2 Method of imaging localized infections
03/24/2010EP2164524A2 Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography
03/24/2010EP2164523A2 Paramagnetic biomolecule complexes and uses thereof in the assessment of organ function
03/24/2010EP1507562B1 Compositions for radioimmunotherapy of brain
03/24/2010CN101679526A Humanized and chimeric anti-TROP-2 antibodies that mediate cancer cell cytotoxicity
03/24/2010CN101678129A Radioactive pet agents for imaging CCR5 in vivo
03/24/2010CN101678121A Modified hydroxypolymer conjugates with killing effect on tumor cells
03/24/2010CN101678118A Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
03/24/2010CN101675997A Prosthetic groups useful in the synthesis of radiopharmaceutical compounds
03/23/2010US7684852 System, formulation, kit and method for tagging colonic residue in an individual
03/23/2010US7683037 Myocardial perfusion imaging method
03/23/2010US7683028 Particularly Kahalalide F, a tridecapeptide with a ring shape side and a lateral side amidated with 5-methylhexanoic acid; anticarcinogenic agent; refractory cancer that does not respond favorably to other treatments; peptides isolated mollusc, Elysia Elysia rufescens and its diet, a green algae
03/23/2010US7683027 preparations of insulin and glucagon; for use when glucagon response to acute hypoglycemia is impaired or lost in patients with advanced Type 1 and Type 2 diabetes
1 ... 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 ... 243